View in EDS

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

Saved in:
Bibliographic Details
Title: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Authors: Lorusso, Domenica (AUTHOR), Xiang, Yang (AUTHOR), Hasegawa, Kosei (AUTHOR), Scambia, Giovanni (AUTHOR), Leiva, Manuel (AUTHOR), Ramos-Elias, Pier (AUTHOR), Acevedo, Alejandro (AUTHOR), Sukhin, Vladyslav (AUTHOR), Cloven, Noelle (AUTHOR), Pereira de Santana Gomes, Andrea J (AUTHOR), Contreras Mejía, Fernando (AUTHOR), Reiss, Ari (AUTHOR), Ayhan, Ali (AUTHOR), Lee, Jung-Yun (AUTHOR), Saevets, Valeriya (AUTHOR), Zagouri, Flora (AUTHOR), Gilbert, Lucy (AUTHOR), Sehouli, Jalid (AUTHOR), Tharavichitkul, Ekkasit (AUTHOR), Lindemann, Kristina (AUTHOR)
Source: Lancet. Apr2024, Vol. 403 Issue 10434, p1341-1350. 10p.
Subjects: Merck KGaA, Clinical trials, Merck & Co. Inc., Cervical cancer, External beam radiotherapy, Volumetric-modulated arc therapy, Chemoradiotherapy, Rectal cancer, Voice disorders
Abstract: Pembrolizumab has shown efficacy in persistent, recurrent, or metastatic cervical cancer. The effect of chemoradiotherapy might be enhanced by immunotherapy. In this phase 3 trial, we assessed the efficacy and safety of adding pembrolizumab to chemoradiotherapy in locally advanced cervical cancer. In this randomised, double-blind, placebo-controlled, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 clinical trial, adults (age ≥18 years) at 176 medical centres in 30 countries with newly diagnosed, high-risk, locally advanced cervical cancer were randomly assigned (1:1) using an interactive voice-response system with integrated web response to receive 5 cycles of pembrolizumab (200 mg) or placebo every 3 weeks plus chemoradiotherapy, followed by 15 cycles of pembrolizumab (400 mg) or placebo every 6 weeks. Randomisation was stratified by planned external beam radiotherapy type (intensity-modulated radiotherapy or volumetric-modulated arc therapy vs non-intensity-modulated radiotherapy or non-volumetric-modulated arc therapy), cervical cancer stage at screening (International Federation of Gynecology and Obstetrics 2014 stage IB2–IIB node positive vs stage III–IVA), and planned total radiotherapy (external beam radiotherapy plus brachytherapy) dose (<70 Gy vs ≥70 Gy equivalent dose in 2 Gy fractions). Primary endpoints were progression-free survival per Response Evaluation Criteria in Solid Tumours version 1.1—by investigator or by histopathologic confirmation of suspected disease progression—and overall survival. Primary analysis was conducted in the intention-to-treat population, which included all randomly allocated participants. Safety was assessed in the as-treated population, which included all randomly allocated patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov , NCT04221945 , and is closed to new participants. Between June 9, 2020, and Dec 15, 2022, 1060 participants were randomly assigned to treatment, with 529 assigned to the pembrolizumab–chemoradiotherapy group and 531 to the placebo–chemoradiotherapy group. At data cutoff (Jan 9, 2023), median follow-up was 17·9 months (IQR 11·3–22·3) in both treatment groups. Median progression-free survival was not reached in either group; rates at 24 months were 68% in the pembrolizumab–chemoradiotherapy group versus 57% in the placebo–chemoradiotherapy group. The hazard ratio (HR) for disease progression or death was 0·70 (95% CI 0·55–0·89, p=0·0020), meeting the protocol-specified primary objective. Overall survival at 24 months was 87% in the pembrolizumab–chemoradiotherapy group and 81% in the placebo–chemoradiotherapy group (information fraction 42·9%). The HR for death was 0·73 (0·49–1·07); these data have not crossed the boundary of statistical significance. Grade 3 or higher adverse event rates were 75% in the pembrolizumab–chemoradiotherapy group and 69% in the placebo–chemoradiotherapy group. Pembrolizumab plus chemoradiotherapy significantly improved progression-free survival in patients with newly diagnosed, high-risk, locally advanced cervical cancer. Merck Sharp & Dohme, a subsidiary of Merck & Co (MSD). [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 176441776
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lorusso%2C+Domenica%22&quot;&gt;Lorusso, Domenica&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Xiang%2C+Yang%22&quot;&gt;Xiang, Yang&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hasegawa%2C+Kosei%22&quot;&gt;Hasegawa, Kosei&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Scambia%2C+Giovanni%22&quot;&gt;Scambia, Giovanni&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Leiva%2C+Manuel%22&quot;&gt;Leiva, Manuel&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ramos-Elias%2C+Pier%22&quot;&gt;Ramos-Elias, Pier&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Acevedo%2C+Alejandro%22&quot;&gt;Acevedo, Alejandro&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sukhin%2C+Vladyslav%22&quot;&gt;Sukhin, Vladyslav&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cloven%2C+Noelle%22&quot;&gt;Cloven, Noelle&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pereira+de+Santana+Gomes%2C+Andrea+J%22&quot;&gt;Pereira de Santana Gomes, Andrea J&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Contreras+Mej&#237;a%2C+Fernando%22&quot;&gt;Contreras Mej&#237;a, Fernando&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Reiss%2C+Ari%22&quot;&gt;Reiss, Ari&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ayhan%2C+Ali%22&quot;&gt;Ayhan, Ali&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lee%2C+Jung-Yun%22&quot;&gt;Lee, Jung-Yun&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Saevets%2C+Valeriya%22&quot;&gt;Saevets, Valeriya&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Zagouri%2C+Flora%22&quot;&gt;Zagouri, Flora&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gilbert%2C+Lucy%22&quot;&gt;Gilbert, Lucy&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sehouli%2C+Jalid%22&quot;&gt;Sehouli, Jalid&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tharavichitkul%2C+Ekkasit%22&quot;&gt;Tharavichitkul, Ekkasit&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lindemann%2C+Kristina%22&quot;&gt;Lindemann, Kristina&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. Apr2024, Vol. 403 Issue 10434, p1341-1350. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Merck+KGaA%22&quot;&gt;Merck KGaA&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Clinical+trials%22&quot;&gt;Clinical trials&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Merck+%26+Co%2E+Inc%2E%22&quot;&gt;Merck &amp; Co. Inc.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cervical+cancer%22&quot;&gt;Cervical cancer&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22External+beam+radiotherapy%22&quot;&gt;External beam radiotherapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Volumetric-modulated+arc+therapy%22&quot;&gt;Volumetric-modulated arc therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Chemoradiotherapy%22&quot;&gt;Chemoradiotherapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Rectal+cancer%22&quot;&gt;Rectal cancer&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Voice+disorders%22&quot;&gt;Voice disorders&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Pembrolizumab has shown efficacy in persistent, recurrent, or metastatic cervical cancer. The effect of chemoradiotherapy might be enhanced by immunotherapy. In this phase 3 trial, we assessed the efficacy and safety of adding pembrolizumab to chemoradiotherapy in locally advanced cervical cancer. In this randomised, double-blind, placebo-controlled, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 clinical trial, adults (age ≥18 years) at 176 medical centres in 30 countries with newly diagnosed, high-risk, locally advanced cervical cancer were randomly assigned (1:1) using an interactive voice-response system with integrated web response to receive 5 cycles of pembrolizumab (200 mg) or placebo every 3 weeks plus chemoradiotherapy, followed by 15 cycles of pembrolizumab (400 mg) or placebo every 6 weeks. Randomisation was stratified by planned external beam radiotherapy type (intensity-modulated radiotherapy or volumetric-modulated arc therapy vs non-intensity-modulated radiotherapy or non-volumetric-modulated arc therapy), cervical cancer stage at screening (International Federation of Gynecology and Obstetrics 2014 stage IB2–IIB node positive vs stage III–IVA), and planned total radiotherapy (external beam radiotherapy plus brachytherapy) dose (&lt;70 Gy vs ≥70 Gy equivalent dose in 2 Gy fractions). Primary endpoints were progression-free survival per Response Evaluation Criteria in Solid Tumours version 1.1—by investigator or by histopathologic confirmation of suspected disease progression—and overall survival. Primary analysis was conducted in the intention-to-treat population, which included all randomly allocated participants. Safety was assessed in the as-treated population, which included all randomly allocated patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov , NCT04221945 , and is closed to new participants. Between June 9, 2020, and Dec 15, 2022, 1060 participants were randomly assigned to treatment, with 529 assigned to the pembrolizumab–chemoradiotherapy group and 531 to the placebo–chemoradiotherapy group. At data cutoff (Jan 9, 2023), median follow-up was 17&#183;9 months (IQR 11&#183;3–22&#183;3) in both treatment groups. Median progression-free survival was not reached in either group; rates at 24 months were 68% in the pembrolizumab–chemoradiotherapy group versus 57% in the placebo–chemoradiotherapy group. The hazard ratio (HR) for disease progression or death was 0&#183;70 (95% CI 0&#183;55–0&#183;89, p=0&#183;0020), meeting the protocol-specified primary objective. Overall survival at 24 months was 87% in the pembrolizumab–chemoradiotherapy group and 81% in the placebo–chemoradiotherapy group (information fraction 42&#183;9%). The HR for death was 0&#183;73 (0&#183;49–1&#183;07); these data have not crossed the boundary of statistical significance. Grade 3 or higher adverse event rates were 75% in the pembrolizumab–chemoradiotherapy group and 69% in the placebo–chemoradiotherapy group. Pembrolizumab plus chemoradiotherapy significantly improved progression-free survival in patients with newly diagnosed, high-risk, locally advanced cervical cancer. Merck Sharp &amp; Dohme, a subsidiary of Merck &amp; Co (MSD). [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=176441776
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(24)00317-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 1341
    Subjects:
      – SubjectFull: Merck KGaA
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Merck & Co. Inc.
        Type: general
      – SubjectFull: Cervical cancer
        Type: general
      – SubjectFull: External beam radiotherapy
        Type: general
      – SubjectFull: Volumetric-modulated arc therapy
        Type: general
      – SubjectFull: Chemoradiotherapy
        Type: general
      – SubjectFull: Rectal cancer
        Type: general
      – SubjectFull: Voice disorders
        Type: general
    Titles:
      – TitleFull: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lorusso, Domenica
      – PersonEntity:
          Name:
            NameFull: Xiang, Yang
      – PersonEntity:
          Name:
            NameFull: Hasegawa, Kosei
      – PersonEntity:
          Name:
            NameFull: Scambia, Giovanni
      – PersonEntity:
          Name:
            NameFull: Leiva, Manuel
      – PersonEntity:
          Name:
            NameFull: Ramos-Elias, Pier
      – PersonEntity:
          Name:
            NameFull: Acevedo, Alejandro
      – PersonEntity:
          Name:
            NameFull: Sukhin, Vladyslav
      – PersonEntity:
          Name:
            NameFull: Cloven, Noelle
      – PersonEntity:
          Name:
            NameFull: Pereira de Santana Gomes, Andrea J
      – PersonEntity:
          Name:
            NameFull: Contreras Mejía, Fernando
      – PersonEntity:
          Name:
            NameFull: Reiss, Ari
      – PersonEntity:
          Name:
            NameFull: Ayhan, Ali
      – PersonEntity:
          Name:
            NameFull: Lee, Jung-Yun
      – PersonEntity:
          Name:
            NameFull: Saevets, Valeriya
      – PersonEntity:
          Name:
            NameFull: Zagouri, Flora
      – PersonEntity:
          Name:
            NameFull: Gilbert, Lucy
      – PersonEntity:
          Name:
            NameFull: Sehouli, Jalid
      – PersonEntity:
          Name:
            NameFull: Tharavichitkul, Ekkasit
      – PersonEntity:
          Name:
            NameFull: Lindemann, Kristina
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 04
              Text: Apr2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 403
            – Type: issue
              Value: 10434
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1